Cargando…

Effect of tocilizumab treatment in mildly-obese patients with coronavirus disease 2019: a case series

BACKGROUND: The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is an increasingly widespread international medical problem. Several randomized trials and observational studies in patients with COVID-19 have been performed. However, the stan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abe, Takashi, Yamaguchi, Fumihiro, Sakakura, Shunsuke, Yamazaki, Yohei, Shikama, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816833/ https://www.ncbi.nlm.nih.gov/pubmed/36618789 http://dx.doi.org/10.21037/atm-2022-49

Ejemplares similares

Pneumothorax with Eosinophilia is an Important Diagnostic Clue for Distinguishing Paragonimiasis from Chronic Eosinophilic Pneumonia: A Case Report
por: Sakakura, Shunsuke, et al.
Publicado: (2023)

Surgical Resection to Treat a Japanese Patient with Pulmonary Coccidioidomycosis
por: Abe, Takashi, et al.
Publicado: (2023)

Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019
por: Gomi, Kuniyo, et al.
Publicado: (2021)

Combination of anti-glycopeptidolipid-core IgA antibody and clinical features for diagnosing potential nontuberculous mycobacterium pulmonary disease in routine practice
por: Iwasaki, Takuya, et al.
Publicado: (2022)

PCR amplification of the erm(41) gene can be used to predict the sensitivity of Mycobacterium abscessus complex strains to clarithromycin
por: Mase, Ayaka, et al.
Publicado: (2020)

Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series
por: Cui, Ran, et al.
Publicado: (2021)

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Hemoptysis following Talc Pleurodesis in a Pneumothorax Patient
por: Kakiuchi, Yusuke, et al.
Publicado: (2017)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

Association of obesity paradox with prognosis of veno‐venous‐extracorporeal membrane oxygenation in patients with coronavirus disease 2019
por: Honzawa, Hiroshi, et al.
Publicado: (2023)

Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
por: Jorgensen, Sarah C.J., et al.
Publicado: (2022)

Effect of Tocilizumab Treatment on Patients with Coronavirus Disease 2019 and Bacteremia: A Retrospective Cohort Study
por: Kuwahara, Masaatsu, et al.
Publicado: (2022)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
por: Tabarsi, Payam, et al.
Publicado: (2021)

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab
por: Morrison, Austin R., et al.
Publicado: (2020)

A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019
por: Lewis, Tyler C., et al.
Publicado: (2020)

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
por: Hartog, Nicholas L., et al.
Publicado: (2021)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
por: Abdullah, Shazia, et al.
Publicado: (2021)

Immunosuppression and cardiovascular dysfunction in patients with severe versus mild coronavirus disease 2019: a case series
por: Bao, Hejing, et al.
Publicado: (2020)

Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series
por: Beltrão, Beatriz Amorim, et al.
Publicado: (2021)

Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients
por: Sirimaturos, Michael, et al.
Publicado: (2020)

Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19)
por: Chen, Chong-xiang, et al.
Publicado: (2021)

Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality
por: Sinha, Pranay, et al.
Publicado: (2021)

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
por: Zhang, Shengyu, et al.
Publicado: (2020)

Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution
por: Ichiyama, Takashi, et al.
Publicado: (2022)

The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases
por: Hazbun, Munir E., et al.
Publicado: (2020)

Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
por: Tanaka, Tomohiro, et al.
Publicado: (2023)

Late acute pulmonary embolism after mild Coronavirus Disease 2019 (COVID-19): a case series
por: Vechi, Hareton Teixeira, et al.
Publicado: (2020)

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients
por: Xu, Lengnan, et al.
Publicado: (2022)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
por: Gao, Qian, et al.
Publicado: (2022)

Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea
por: Jeon, Jaehyun, et al.
Publicado: (2022)

Obesity and Coronavirus Disease 2019
por: Kim, Min-Ji, et al.
Publicado: (2021)

Obesity and Coronavirus Disease 2019
por: Fei, Sijia, et al.
Publicado: (2022)

Tocilizumab for refractory morphea in adults: A case series
por: Lonowski, Sarah, et al.
Publicado: (2022)

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*
por: Tom, Jennifer, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_22m524kkodgdpn1s163uagaa7l